Voluntary Announcement Amendments to the Articles of Association

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2023

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2023

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2023

Articles of Association

Poll Results of the Annual General Meeting Held on 29 May 2023

Boan Biotech’s BA1202 Approved for Clinical Trial The First Novel CEA/CD3 Bispecific Antibody in China

Yantai, May 16, 2023 – Boan Biotech announced today that its BA1202, a CEACAM5 (CEA)/CD3 bispecific antibody, has been approved for a clinical trial by the Center for Drug Evaluation of China...

Voluntary Announcement Approval Obtained for Initiating Clinical Trial for the Novel Bispecific Antibody BA1202 in China

Patient Enrollment Completed for Phase III Clinical Trial of Boan Biotech’s Dulaglutide Injection BA5101 in China

Yantai, May 15, 2023 – Boan Biotech today announced the completion of patient enrollment for the Phase III clinical trial (a comparative clinical study of efficacy and safety) of the company&rsq...

Boan Biotech to Attend PEGS Boston 2023 with Its Novel ADC BA1302

Yantai, China, May 15, 2023—Boan Biotech is to present the results of its research on BA1302, a novel CD228-directed antibody drug conjugate (ADC) developed by the company, as a poster at the 19th Es...